Case Series of 6 Fetuses With Osteogenesis Imperfecta Type II: A Retrospective Study of Heart Pathology
- PMID: 39189102
- PMCID: PMC11762339
- DOI: 10.1177/10935266241272511
Case Series of 6 Fetuses With Osteogenesis Imperfecta Type II: A Retrospective Study of Heart Pathology
Abstract
Introduction: Osteogenesis imperfecta (OI) is a rare genetic disorder characterized by bone fragility. While skeletal manifestations are well documented, few studies have explored the effect of OI on the fetal heart. This retrospective case series investigates cardiac pathology in OI type II fetuses, aiming to address this gap.
Methods: Medical records and autopsy reports of 6 genetically confirmed OI type II cases were examined. Fetuses had pathogenic variants in COL1A1 or PPIB, inducing structural defects in collagen type I. In addition to hematoxylin and eosin and Elastic van Gieson staining, the expression of collagen type I, COL1A1 and COL1A2 chains was examined by immunohistochemistry.
Results: Immunohistochemistry confirmed robust expression of collagen type I throughout the heart. Five fetuses had normal heart weight, while 1 had a low heart weight in the context of generalized growth retardation. None displayed structural heart anomalies.
Conclusion: This study reveals robust collagen type I expression in the hearts of OI type II fetuses without structural anomalies. We hypothesize that collagen type I abnormalities may not be causative factors for heart anomalies during early embryonic development. Instead, their impact may be conceivably related to an increased susceptibility to degenerative changes later in life.
Keywords: COL1A1; COL1A2; OI type II; collagen type I; heart pathology; osteogenesis imperfecta.
Conflict of interest statement
Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures


Similar articles
-
A new Col1a1 conditional knock-in mouse model to study osteogenesis imperfecta.J Bone Miner Res. 2024 Dec 31;40(1):114-124. doi: 10.1093/jbmr/zjae189. J Bone Miner Res. 2024. PMID: 39566076
-
Anti-transforming growth factor-β treatment shows increased bone mass and strength in a novel mouse model for osteogenesis imperfecta type I.J Bone Miner Res. 2025 Jun 25;40(7):881-890. doi: 10.1093/jbmr/zjaf068. J Bone Miner Res. 2025. PMID: 40358008
-
Galunisertib downregulates mutant type I collagen expression and promotes MSCs osteogenesis in pediatric osteogenesis imperfecta.Biomed Pharmacother. 2024 Jun;175:116725. doi: 10.1016/j.biopha.2024.116725. Epub 2024 May 13. Biomed Pharmacother. 2024. PMID: 38744219
-
Dental Abnormalities in Osteogenesis Imperfecta: A Systematic Review.Calcif Tissue Int. 2024 Nov;115(5):461-479. doi: 10.1007/s00223-024-01293-2. Epub 2024 Sep 18. Calcif Tissue Int. 2024. PMID: 39294450 Free PMC article.
-
Should we offer prenatal exome sequencing for intrauterine growth restriction or short long bones? A systematic review and meta-analysis.Am J Obstet Gynecol. 2023 Apr;228(4):409-417.e4. doi: 10.1016/j.ajog.2022.09.045. Epub 2022 Oct 7. Am J Obstet Gynecol. 2023. PMID: 36209938
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous